Aclaris Therapeutics, Inc. (ACRS) Financial Statements
Aclaris Therapeutics, Inc. (ACRS) reported trailing twelve-month revenue of $8.2M (down 51.0% year on year) and net income of -$75.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$62.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ACRSAclaris Therapeutics, Inc.Follow ACRS — free
—
Price chart with a free account
- Market cap
- 552.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.7 | 6.2 | 4.2 | 6.5 | 6.8 | 29.8 | 31.2 | 18.7 | 7.8 | 8.2 | |
| Gross profit | 0.5 | 3.2 | 0.2 | 1.3 | 2.0 | 25.7 | 27.8 | 15.9 | 5.7 | 6.5 | |
| Research & development | 35.8 | 60.8 | 64.2 | 29.3 | 43.8 | 77.8 | 98.4 | 33.6 | 52.6 | 63.3 | |
| Operating income | -54.4 | -84.8 | -111.1 | -50.9 | -89.7 | -89.9 | -97.4 | -141.9 | -76.4 | -86.3 | |
| Pre-tax income | -70.4 | -82.1 | -113.5 | -51.3 | -90.9 | -86.9 | -88.8 | -132.1 | -64.9 | -75.7 | |
| Income tax | -1.8 | — | — | -0.2 | — | — | -0.4 | — | — | — | |
| Net income | -68.5 | -132.7 | -161.4 | -51.0 | -90.9 | -86.9 | -88.5 | -132.1 | -64.9 | -75.7 | |
| Diluted EPS ($) | -2.44 | -4.03 | -3.90 | -1.20 | -1.60 | -1.33 | -1.27 | -1.71 | -0.53 | -0.53 | |
| Diluted shares (mn) | — | — | — | — | 56.7 | 65.2 | 69.8 | 77.3 | 122.6 | — |
USD millions · SEC XBRL
Aclaris Therapeutics, Inc. — questions
- What is Aclaris Therapeutics, Inc.'s revenue?
- $8.2M over the twelve months to 2026-06-30, down 51.0% year on year, from its 10-Q and 10-K filings.
- What is Aclaris Therapeutics, Inc.'s net income?
- -$75.7M over the twelve months to 2026-06-30.
- What is Aclaris Therapeutics, Inc.'s free cash flow?
- -$62.2M over the twelve months to 2026-06-30.
- What are Aclaris Therapeutics, Inc.'s diluted earnings per share?
- $-0.53 over the twelve months to 2026-06-30.
Every figure on this page comes from Aclaris Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.